Status:
COMPLETED
Evaluation of [18F]-FMISO for Non Operated Glioblastoma
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Hypoxia is recognized to be an independent predictor of clinical outcome in oncology. PET using \[18F\]-FMISO has been described to be useful for the non invasive assessment of hypoxia in cancer. The ...
Detailed Description
Hypoxia is one of the worst prognostic factors of clinical outcome in glioblastomas. Today, it is well admitted that hypoxia is heterogeneous, variable within different tumour types and varied spatial...
Eligibility Criteria
Inclusion
- Patients over 18
- Patients with a malignant tumour glioblastomas proposed for a radical treatment consisting in conformational radiotherapy and/or chemotherapy
- Signed informed consent
Exclusion
- Patients who can't undergo radiotherapy or chemotherapy
- Patients with distant metastases known before inclusion except renal cancer where patients with metastases can be included
- Patients suffering of a second cancer or treated before by radiotherapy in the tumour site.
- Pregnant and breast feeding women, women in age to procreate without contraception
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00906893
Start Date
June 1 2009
End Date
January 1 2013
Last Update
February 28 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux - Hôpital Pellegrin
Bordeaux, France, 33076